Tessera Therapeutics

Tessera is a biotechnology company pioneering a new approach in genetic medicine known as GENE WRITING technology.

Tessera Therapeutics' mission is to cure disease by writing in the code of life.

Tessera Therapeutics was founded by Flagship Pioneering in 2018. The company is headquartered in Cambridge, Massachusetts.


Tessera's GENE WRITING consists of multiple technology platforms designed to offer scientists and clinicians the ability to write therapeutic messages into the human genome, thereby curing diseases at their source.


The GENE WRITING platform allows the correction of single nucleotides, the deletion or insertion of short sequences of DNA, and the writing of entire genes into the genome, offering the potential for a new category of genetic medicines with broad applications both in vivo and ex vivo.


Tessera has evaluated tens of thousands of natural and synthetic MGEs to create GENE WRITER candidates with the ability to write therapeutic messages into the human genome. 


Tessera is backed by Flagship Pioneering, Abu Dhabi Investment Authority (ADIA), SoftBank Vision Fund 2, Qatar Investment Authority (QIA), Alaska Permanent Fund Corporation, Altitude Life Science Ventures, ARTIS Ventures, Cormorant Asset Management, and others. The company raised over $300M in Series C round on Apr 19, 2022. This brings Tessera's total funding to $530M to date.



  • Year founded: 2018
  • Funding Info: $530M over 2 Rounds (Latest Funding Type: Series C)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Cambridge
  • State: Massachusetts
  • Country: United States
Related businesses